Difference between revisions of "Richter S, et al. Invest N. Drugs (2014) cited as Ref 588 in DOI: 10.1038/s41392-020-0110-5 (Q9851)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Volume (P103): 32, #quickstatements; #temporary_batch_1590009084631)
(‎Created claim: Page(s) (P105): 243-249, #quickstatements; #temporary_batch_1590074839150)
 
(One intermediate revision by the same user not shown)
Property / title
 +
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) (English)
Property / title: A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) (English) / rank
 +
Normal rank
Property / Page(s)
 +
243-249
Property / Page(s): 243-249 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Richter S, et al. Invest N. Drugs (2014) cited as Ref 588 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Richter S
    0 references
    2014
    0 references
    Invest N. Drugs
    0 references
    32
    0 references
    A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) (English)
    0 references
    243-249
    0 references